Summary (tl;dr)

A highly mutated COVID-19 subvariant, colloquially named "Cicada" (BA.3.2), is trending due to concerns over its transmissibility, potential for immune evasion, and a surge in public searches for its symptoms in 2026.

Essential Background

The SARS-CoV-2 virus continues to evolve, leading to the regular emergence of new variants that impact global public health. These variants are closely monitored by health organizations worldwide to assess their potential effects on disease severity, vaccine effectiveness, and population immunity. The public remains actively engaged in understanding these developments, often turning to search engines for information on new strains and their associated symptoms.

The Full Story

Google Trends data indicates a significant rise in searches for "cicada covid variant ba 3.2" and "covid symptoms 2026," reflecting escalating public interest in a newly identified sublineage of the SARS-CoV-2 virus. Officially known as BA.3.2, this variant has been nicknamed "Cicada" because it emerged in notable numbers after a period of seemingly going undetected, much like the insect. First identified in South Africa in November 2024, the "Cicada" variant has since been detected in at least 23 countries and 25 U.S. states, including through wastewater surveillance and clinical samples. Health experts are particularly noting its highly divergent genetic profile, with 70 to 75 mutations in its spike protein, which raises questions about its ability to evade existing immunity and how well current vaccines match the strain. While its symptoms are reported to be similar to other Omicron variants, including cough, fatigue, fever, body aches, sore throat, and headache, the intense public interest underscores a desire to understand any subtle differences in presentation in 2026. The U.S. Centers for Disease Control and Prevention (CDC) is actively evaluating BA.3.2 for its transmissibility, immune evasion, and clinical impact.

Why It Matters

The surge in searches for the "Cicada" variant and "covid symptoms 2026" highlights ongoing public vigilance and concern over the evolving nature of the COVID-19 pandemic. The variant's numerous mutations suggest it could partially evade existing immune defenses, potentially increasing the likelihood of breakthrough infections even in vaccinated or previously infected individuals. Public interest in specific symptoms indicates a desire to differentiate this variant from prior strains and other respiratory illnesses, influencing personal health decisions and precautionary measures. The continuous emergence of highly mutated variants like BA.3.2 underscores the critical need for sustained global surveillance, research into variant characteristics, and adaptive public health strategies to manage the virus's long-term impact.

Geographic Location

• South Africa (first identified the BA.3.2 "Cicada" variant in November 2024)
• United States (variant detected in at least 25 states via wastewater surveillance and clinical samples; CDC is evaluating it)
• Globally (variant detected in at least 23 countries)